Industry News
Pharmaceutical Industry News
Book Review: ‘The Ego Trip,’ by Kimon de Greef
Kimon de Greef’s “The Ego Trip” is an enthralling, galling journey into the deeply weird underbelly of the psychedelic renaissance.
After a yearslong struggle, Jazz…
After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer.
What’s the Best Way to Treat Heartburn?
Tums, Pepcid, Gaviscon — over-the-counter medications can reduce symptoms in different ways. Here’s how to find the ideal one for you.
In a milestone for IgA…
In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate seen in healthy
Months after reports first linked…
Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
Who should be a 2026 Fiercest…
Who should be a 2026 Fiercest Woman in Life Sciences? Nominations are open for women making an impact across pharma, biotech, medtech and beyond. The deadline is Sept. 18.
Supernus and Indivior have agreed…
Supernus and Indivior have agreed to merge in an all-stock transaction to form a new central nervous system-focused biopharma. They are expected to have combined revenue of $2.2 billion this year, leveraging $125 million in
Hackers recently accessed…
Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company data, the company disclosed in a securities filing on Friday.
A week after Johnson & Johnson…
A week after Johnson & Johnson moved to resolve claims that its Johnson’s Baby Powder caused ovarian cancer, Novartis’ generics and biosimilars spinout Sandoz is plotting its own escape from long-running U.S. litigation, this time
Gerresheimer, a Germany-based…
Gerresheimer, a Germany-based packaging company that specializes in drug delivery systems and glass and plastic packaging, sold two of its units to the private equity group Apax Partners in a deal valued at €1.5 billion
Combining the two drugmakers would…
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
Novartis’ blockbuster…
Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, securing a U.S. nod in an earlier form of prostate cancer that nearly doubles the
Amylyx’s patient education…
Amylyx’s patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a rare and often overlooked complication of weight-loss surgery.
A notice from the Health Resources…
A notice from the Health Resources & Services Administration sidelines covered entities' attestations of substantial administrative burden and sets the mulligan program into motion, targeting a Jan. 1 start and 25 potentially eligible products.
A Daiichi Sankyo quarterly report…
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses.
Seven years after it was approved,…
Seven years after it was approved, AbbVie's Skyrizi has proven to be a more-than-adequate replacement for Humira, which was formerly the world's top-selling drug. In the second quarter, the IL-23 inhibitor generated sales of $5.55
Reporting a new miss in one…
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
Shionogi’s “Got the Call, Make…
Shionogi's “Got the Call, Make the Call” campaign for COVID antiviral Xocova kicks off with a TV ad depicting a mother getting a call from her COVID-infected son.
Legend Biotech’s Ying Huang,…
Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly deleted—a clinical trial plan to test its PD-1xVEGF bispecific in combination with its TROP2 ADC. The FDA approved
In hopes of challenging Incyte’s…
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo.